7月28日,#恒瑞医药 发布公告,将HRS-9821项目的全球独家权利(不包括中国大陆、香港特别行政区、澳门特别行政区及中国台湾地区)和至多11个项目的全球独家许可的独家选择权(不包括中国内地、中国港澳地区和中国台湾地区)有偿许可给跨国药企葛兰素史克GSK。葛兰素史克GSK将向恒瑞医药支付5亿美元的首付款,未来基于成功开发、注册和销售里程碑付款的潜在总金额或达120亿美元。恒瑞医药公告受利好消息...
Source Link7月28日,#恒瑞医药 发布公告,将HRS-9821项目的全球独家权利(不包括中国大陆、香港特别行政区、澳门特别行政区及中国台湾地区)和至多11个项目的全球独家许可的独家选择权(不包括中国内地、中国港澳地区和中国台湾地区)有偿许可给跨国药企葛兰素史克GSK。葛兰素史克GSK将向恒瑞医药支付5亿美元的首付款,未来基于成功开发、注册和销售里程碑付款的潜在总金额或达120亿美元。恒瑞医药公告受利好消息...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.